Founder’s Playbook: From Target to Development Strategy

The five decisions between a validated target and a clinical program

Feb 22 • age1 and Lynetta Wang

3

Five Unconquered Frontiers for Longevity biotech: Our 2026 Call for Proposals

We're looking for enabling technologies that propel therapeutic asset concepts to have the potential to go on to become civilization-changing medicines

Feb 16 • age1 and Satvik Dasariraju

7

1

The Cheapest Insurance in Drug Development

A framework for target validation before the million-dollar commitment

Feb 15 • age1 and Lynetta Wang

6

Hunting Targets in Their Native Environment

Betting on Biology III: A strategic framework for context-preserving target discovery

Feb 7 • age1 and Lynetta Wang

14

2

January 2026

How Scalable Perturbation Sequencing Rewrites Causal Target Discovery

From tracking cell survival to programming functional identity through billion-cell atlases

Jan 30 • age1 and Lynetta Wang

9

2

1

Betting on Biology: Part I

How to choose target that work, and succeed.

Jan 21 • age1 and Lynetta Wang

27

2

3

September 2025

Anatomy of a Biotech Failure: Part II

learning from the lessons of the graveyard

Sep 3, 2025 • age1 and Soleil Wizman

23

2

2

August 2025

Anatomy of a Biotech Failure: Part I

Eight Case Studies in Recent Shutdown History

Aug 28, 2025 • age1 and Soleil Wizman

64

1

July 2025

age1’s 2025 1st Annual Pharma Aging Report Card

Grading the giants on their race to extend human healthspan

Jul 29, 2025 • age1 and Soleil Wizman

26

4

Is this aging?

So you wanna build an aging company?

Jul 3, 2025 • Sarah Constantin, Lily Clayton, and age1

24

5

7

March 2024

A call to arms to save the genome

How protecting our genetic code can turn the tide against death

Mar 28, 2024 • age1 and Alan Tomusiak

17

1

What we wish we knew entering the aging field

The longevity funnel framework (LFF)

Mar 14, 2024 • age1 and Maggie Li

31

3